Sirnaomics cleared to start first trial of RNAi lead in cancer | Digital Science

Gene-silencing specialist Sirnaomics has been cleared to start trials of its STP705 drug in bile duct , its first oncology indication.

The FDA has approved the biotech's application to test the RNA interference (RNAi) candidate—which targets TGF-β1 and COX-2—in patients with bile duct cancer (cholangiocarcinoma, or CCA), adding to an earlier green light for a of the drug as a scar-reducing treatment.

The biotech says STP705 downregulates cancer-associated fibroblast (CAF) activity within the tumor microenvironment, inhibiting tumor formation. It was given orphan status for CCA and a fibrotic disease affecting the bile duct, primary sclerosing cholangitis (PSC), last year.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

The approval comes shortly after the regulator approved the first-ever drug in the category—Alnylam's rare disease therapy patisiran—and is another indicator of the rapid emergence of RNA-targeting drugs in the biopharma sector.

Sirnaomics' founder and CEO Patrick Lu, Ph.D., said the patisiran approval “validates the RNAi class of therapeutics and it is our belief that the industry will see great enthusiasm and expanded discovery and development of novel RNAi therapeutics for many disease applications.”

The Gaithersburg, Maryland-based biotech has been working on RNAi therapeutics since its formation more than a decade ago, and it raised $25 million from Chinese investors in a third-round financing in June.

At the time, the company said it planned to have two clinical trials running before the end of the year, and it plans to move ahead quickly with STP705 in The U.S., Europe and China, where it has a longstanding partnership with Guangzhou Xiangxue Pharma.

Sirnaomics' Chief Medical Officer Michael Molyneaux, M.D., said the clearance to start trials in CCA is important, as this is “a devastating form of liver cancer with very high mortality and no effective therapy.”

It is the second most common hepatic primary malignancy, accounting for 15%-20% of all liver cancer cases. It is particularly common in Asia, although its incidence has increased quickly in the West in recent years, with around 5,000 new cases reported in the U.S. every year.

You might also like

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More